[1] Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J]. N Engl J Med, 2002, 346(2):92-98.
[2] Liu H, Liang Y, Li Y, et al. Gene silencing of BAG-1 modulates apoptotic genes and sensitizes lung cancer cell lines to cisplatin-induced apoptosis[J]. Cancer Biol Ther, 2010, 9(10):832-840.
[3] Rosell R, Felip E. Predicting response to paclitaxel/carboplatin-based therapy in non-small cell lung cancer[J]. Semin Oncol, 2001, 28(4 Suppl 14):37-44.
[4] Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin[J]. Crit Rev Oncol Hematol, 2007, 63(1):12-31.
[5] Danesi R, Pasqualetti G, Giovannetti E, et al. Pharmacogenomics in non-small-cell lung cancer chemotherapy[J]. Adv Drug Deliv Rev, 2009, 61(5):408-417.
[6] Toschi L, Cappuzzo F. Impact of biomarkers on non-small cell lung cancer treatment[J]. Target Oncol, 2010, 5(1):5-17.
[7] 杨志坚, 刘德森, 陈发龙, 等. 肺癌组织中 RRM1 表达对预测 GP 化疗方案疗效的作用[J]. 中国癌症防治杂志, 2009, 1(2):124-126.
[8] Davidson JD, Ma L, Flagella M, et al. An increase in the expression of ribonucleotide reductase large subunit is associated with gemcitabine resistance in non-small cell lung cancer cell lines[J]. Cancer Res, 2004, 64(11):3761-3766.
[9] Zhou W, Liu G, Park S, et al. Gene-smoking interaction associations for the ERCC1 polymorphisms in the risk of lung cancer[J]. Cancer Epidemiol Biomarkers Prev, 2005, 14(2):491-496.
[10] Zhou W, Gurubhagavatula S, Liu G, et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy [J]. Clin Cancer Res, 2004, 10(15):4939-4943.
[11] Yan D, Wei P, An G, et al. Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage Ⅲ/N2non-small cell lung cancer[J]. J Cardiothorac Surg, 2013, 8 (1):141-149.